# EDGAR Filing Document

**Accession Number:** 0001636282
**File Stem:** 0001628280-26-011614
**Filing Date:** 2026-2
**Character Count:** 2586
**Document Hash:** 232ece1ae4bff58c43cd616f91e4c556
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-011614.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0001628280-26-011614

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Spyre Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001636282
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464312787
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT STREET
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 6176515940

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT STREET
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeglea BioTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150311

**SPYRE THERAPEUTICS, INC.**

221 Crescent Street

Building 23, Suite 105

Waltham, Massachusetts 02453

(617) 651-5940

February 25, 2026

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| RE: | Spyre Therapeutics, Inc. |
| | Registration Statement on Form S-3 (File No. 333-293600) |
| | Request for Acceleration |

---

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Spyre Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-293600) (the "<u>Registration Statement</u>") be accelerated by the Securities and Exchange Commission so that it will be declared effective at 4:00 p.m. EST on February 27, 2026, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Thomas Danielski of Ropes & Gray LLP at <u>Thomas.Danielski@ropesgray.com</u> or (617) 235-4961.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **SPYRE THERAPEUTICS, INC.** | **SPYRE THERAPEUTICS, INC.** |
| By: | /s/ Cameron Turtle, DPhil |
|  | Cameron Turtle, DPhil |
|  | Chief Executive Officer and Director |

---

<br>